Highlights Bristol-Myers Squibb Company

Equities

BMY

US1101221083

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2026-02-09 pm EST			5-day change	1st Jan Change
60.77 ^USD	-1.97%		+8.73%	+12.66%

Feb. 09	AstraZeneca's Evinova Enters Clinical Development AI Partnership Deal	MT
Feb. 06	Wells Fargo Adjusts Bristol-Myers Squibb PT to $60 From $55, Maintains Equal Weight Rating	MT

Highlights

Feb. 09	AstraZeneca's Evinova Enters Clinical Development AI Partnership Deal	MT
Feb. 05	Sector Update: Health Care Stocks Softer Late Afternoon	MT
Feb. 05	Bayer says its experimental blood thinner cuts risk of stroke recurrence by 26%	RE
Feb. 05	Sector Update: Health Care Stocks Softer Thursday Afternoon	MT
Feb. 05	Bristol Myers forecasts upbeat 2026, expects Eliquis price cut to pay off	RE
Feb. 05	Sector Update: Health Care Stocks Lean Lower Premarket Thursday	MT
Feb. 05	Sector Update: Health Care	MT
Feb. 05	Bristol-Myers Squibb expects 2026 adjusted EPS $6.05 to $6.35 vs IBES estimate $6.02	RE
Feb. 05	Tech Set to Drag Wall Street Down Again After Alphabet and Qualcomm
Feb. 05	Bristol-Myers Squibb Company Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
Feb. 05	Bristol Myers forecasts upbeat 2026, expecting Eliquis price cut to pay off	RE
Feb. 05	Bristol-Myers Q4 Non-GAAP Earnings Fall, Revenue Rises; 2026 Guidance Set -- Shares Up Pre-Bell	MT
Feb. 05	Earnings Flash (BMY) Bristol-Myers Squibb Posts Q4 Revenue $12.50B, vs. FactSet Est of $12.28B	MT
Feb. 05	Earnings Flash (BMY) Bristol-Myers Squibb Posts Q4 Adjusted EPS $1.26, vs. FactSet Est of $1.23	MT
Feb. 05	Bristol Myers Squibb 4Q Revenue Ticks Up on Immuno-Oncology Growth	DJ
Feb. 05	On the Rise, Paris Stands Alone Among Major European Markets
Feb. 04	Oxford BioMedica expands cancer therapy deal with Bristol-Myers Squibb	AN
Feb. 04	Oxford Biomedica Enters Commercial Supply Deal for Lentiviral Vectors	MT
Feb. 03	US FDA rejects AstraZeneca's easier-to-use version of lupus therapy	RE
Feb. 02	Lupin Launches Generic Cancer Drug in US	MT
Jan. 29	Piramal Pharma Limited entered into an agreement to acquire Kenalog Brand of Bristol-Myers Squibb Company.	CI
Jan. 27	Cms announces selection of drugs for third cycle of the Medicare drug price negotiation program	RE
Jan. 23	India's Cipla posts steeper-than-expected quarterly profit slump on tumour drug supply crunch	RE
Jan. 22	Janux Therapeutics, Inc. Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop A Novel Tumor-Activated Therapeutic for Solid Tumors	CI
Jan. 22	Bristol-Myers Squibb, Janux Therapeutics Sign Deal to Develop Cancer Drug	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Filters

Headlines

Technical Analysis: Bristol-Myers Squibb hesitates at a critical juncture

August 28, 2025 at 03:51 am EDT